Patricia J. McLaughlin - Publications

Affiliations: 
Anatomy Pennsylvania State University, State College, PA, United States 
Area:
Medicine and Surgery

240 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 McLaughlin PJ, Sassani JW, Diaz D, Zagon IS. Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats. Journal of Diabetes and Clinical Research. 5: 1-10. PMID 37304310 DOI: 10.33696/diabetes.4.054  0.375
2021 Purushothaman I, Zagon IS, Sassani JW, Mclaughlin PJ. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats. Experimental and Therapeutic Medicine. 22: 687. PMID 33986852 DOI: 10.3892/etm.2021.10119  0.302
2020 Zagon IS, Sassani JW, Purushothaman I, McLaughlin PJ. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications. Experimental Biology and Medicine (Maywood, N.J.). 1535370220972060. PMID 33203224 DOI: 10.1177/1535370220972060  0.319
2020 Zagon IS, Sassani JW, Purushothaman I, McLaughlin PJ. Dysregulation of the OGF-OGFr pathway correlates with elevated serum OGF and ocular surface complications in the diabetic rat. Experimental Biology and Medicine (Maywood, N.J.). 1535370220940273. PMID 32640891 DOI: 10.1177/1535370220940273  0.349
2020 McLaughlin PJ, Sassani JW, Zagon IS. Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications. Journal of Cellular Immunology. 2: 42-46. PMID 32368758 DOI: 10.33696/immunology.1.018  0.332
2019 Titunick MB, Lewis GS, Cain JD, Zagon IS, McLaughlin PJ. Blockade of the OGF-OGFr pathway in diabetic bone. Connective Tissue Research. 1-9. PMID 30931654 DOI: 10.1080/03008207.2019.1593396  0.439
2019 McLaughlin PJ, Sassani JW, Titunick MB, Zagon IS. Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes. Bmc Ophthalmology. 19: 35. PMID 30691415 DOI: 10.1186/S12886-019-1044-Y  0.304
2018 Zagon IS, McLaughlin PJ. Intermittent blockade of OGFr and treatment of autoimmune disorders. Experimental Biology and Medicine (Maywood, N.J.). 1535370218817746. PMID 30541348 DOI: 10.1177/1535370218817746  0.356
2018 Ludwig MD, Zagon IS, McLaughlin PJ. Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis. Experimental Biology and Medicine (Maywood, N.J.). 1535370217749830. PMID 29307283 DOI: 10.1177/1535370217749830  0.393
2018 Cain JD, Titunick M, McLaughlin P, Zagon I. Effects of Local Opioid Antagonist on Diabetic Fracture Rat Model Foot & Ankle Orthopaedics. 3: 2473011418S0017. DOI: 10.1177/2473011418S00178  0.402
2017 McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS. Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds. Advances in Wound Care. 6: 279-288. PMID 28894635 DOI: 10.1089/Wound.2016.0725  0.444
2017 Ludwig MD, Zagon IS, McLaughlin PJ. Serum [Met(5)]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. Experimental Biology and Medicine (Maywood, N.J.). 1535370217724791. PMID 28766982 DOI: 10.1177/1535370217724791  0.419
2017 Stockdale DP, Titunick MB, Biegler JM, Reed JL, Hartung AM, Wiemer DF, McLaughlin PJ, Neighbors JD. Selective opioid growth factor receptor antagonists based on a stilbene isostere. Bioorganic & Medicinal Chemistry. PMID 28693915 DOI: 10.1016/J.Bmc.2017.06.035  0.45
2017 Ludwig MD, Zagon IS, McLaughlin PJ. Elevated serum [Met(5)]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis. Brain Research Bulletin. PMID 28647454 DOI: 10.1016/J.Brainresbull.2017.06.015  0.319
2015 Kren NP, Zagon IS, McLaughlin PJ. Nuclear export of opioid growth factor receptor is CRM1 dependent. Experimental Biology and Medicine (Maywood, N.J.). PMID 26429201 DOI: 10.1177/1535370215605585  0.371
2015 Hammer LA, Waldner H, Zagon IS, McLaughlin PJ. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Experimental Biology and Medicine (Maywood, N.J.). PMID 26202376 DOI: 10.1177/1535370215596384  0.328
2015 McLaughlin PJ, Zagon IS. Duration of Opioid Receptor Blockade Determines Biotherapeutic Response. Biochemical Pharmacology. PMID 26119823 DOI: 10.1016/J.Bcp.2015.06.016  0.49
2015 Kren NP, Zagon IS, McLaughlin PJ. Mutations in the opioid growth factor receptor in human cancers alter receptor function. International Journal of Molecular Medicine. 36: 289-93. PMID 26005722 DOI: 10.3892/Ijmm.2015.2221  0.405
2015 McLaughlin PJ, McHugh DP, Magister MJ, Zagon IS. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis. Bmc Immunology. 16: 24. PMID 25906771 DOI: 10.1186/S12865-015-0093-0  0.33
2015 Hammer LA, Zagon IS, McLaughlin PJ. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis. Brain Research Bulletin. 112: 42-51. PMID 25647234 DOI: 10.1016/J.Brainresbull.2015.01.009  0.384
2015 Worley B, Zagon I, McLaughlin P. Opioid growth factor receptor (OGFR) expression is downregulated with progression of triple negative breast cancer International Journal of Cancer Therapy and Oncology. 3: 347. DOI: 10.14319/Ijcto.34.7  0.421
2014 Immonen JA, Zagon IS, McLaughlin PJ. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing. Experimental Biology and Medicine (Maywood, N.J.). 239: 1300-9. PMID 25030485 DOI: 10.1177/1535370214543061  0.53
2014 Immonen JA, Zagon IS, McLaughlin PJ. Topical Naltrexone as Treatment for Type 2 Diabetic Cutaneous Wounds. Advances in Wound Care. 3: 419-427. PMID 24940556 DOI: 10.1089/Wound.2014.0543  0.435
2014 Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World Journal of Gastroenterology : Wjg. 20: 2218-23. PMID 24605021 DOI: 10.3748/Wjg.V20.I9.2218  0.45
2014 McLaughlin PJ, Zagon IS. Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers. Expert Review of Anticancer Therapy. 14: 247-50. PMID 24397732 DOI: 10.1586/14737140.2014.867234  0.309
2014 Zagon IS, Sassani JW, Immonen JA, McLaughlin PJ. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone. Clinical & Experimental Ophthalmology. 42: 159-68. PMID 23777539 DOI: 10.1111/Ceo.12144  0.377
2014 McLaughlin PJ. Opioid Antagonists Enhance Diabetic Wound Closure: A New Therapy Translational Medicine. 4. DOI: 10.4172/2161-1025.1000142  0.421
2013 Immonen JA, Zagon IS, Lewis GS, McLaughlin PJ. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Experimental Biology and Medicine (Maywood, N.J.). 238: 1127-35. PMID 23986225 DOI: 10.1177/1535370213502632  0.399
2013 Hammer LA, Zagon IS, McLaughlin PJ. Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor. Brain Research Bulletin. 98: 122-31. PMID 23973432 DOI: 10.1016/J.Brainresbull.2013.08.001  0.365
2013 Zagon IS, Porterfield NK, McLaughlin PJ. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer. Experimental Biology and Medicine (Maywood, N.J.). 238: 589-99. PMID 23918871 DOI: 10.1177/1535370213489492  0.468
2013 Zagon IS, Donahue R, McLaughlin PJ. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Experimental Biology and Medicine (Maywood, N.J.). 238: 579-87. PMID 23856908 DOI: 10.1177/1535370213488483  0.7
2013 McLaughlin PJ, Immonen JA, Zagon IS. Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis. Experimental Biology and Medicine (Maywood, N.J.). 238: 733-43. PMID 23788174 DOI: 10.1177/1535370213492688  0.423
2013 Rogosnitzky M, Finegold MJ, McLaughlin PJ, Zagon IS. Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Investigational New Drugs. 31: 1066-70. PMID 23275062 DOI: 10.1007/S10637-012-9918-3  0.33
2013 Campbell AM, Zagon IS, McLaughlin PJ. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis. Brain Research Bulletin. 90: 43-51. PMID 22985690 DOI: 10.1016/J.Brainresbull.2012.09.001  0.391
2013 Zagon IS, McLaughlin PJ. Endogenous Opioids and the Treatment of Multiple Sclerosis Journal of Neurology and Neurophysiology. 2014. DOI: 10.4172/2155-9562.S12-011  0.371
2012 Campbell AM, Zagon IS, McLaughlin PJ. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis. Brain Research. 1472: 138-48. PMID 22820301 DOI: 10.1016/J.Brainres.2012.07.006  0.369
2012 McLaughlin PJ, Zagon IS. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease. Biochemical Pharmacology. 84: 746-55. PMID 22687282 DOI: 10.1016/J.Bcp.2012.05.018  0.514
2012 Zagon IS, Campbell AM, Sassani JW, McLaughlin PJ. Spontaneous episodic decreased tear secretion in rats is related to opioidergic signaling pathways. Investigative Ophthalmology & Visual Science. 53: 3234-40. PMID 22511629 DOI: 10.1167/Iovs.11-9051  0.39
2012 McLaughlin PJ, Keiper CL, Verderame MF, Zagon IS. Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 302: R1084-90. PMID 22338080 DOI: 10.1152/Ajpregu.00670.2011  0.417
2012 Donahue RN, McLaughlin PJ, Zagon IS. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Experimental Biology and Medicine (Maywood, N.J.). 237: 167-77. PMID 22328595 DOI: 10.1258/Ebm.2011.011321  0.671
2012 Fanning J, Hossler CA, Kesterson JP, Donahue RN, McLaughlin PJ, Zagon IS. Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. Gynecologic Oncology. 124: 319-24. PMID 22037317 DOI: 10.1016/J.Ygyno.2011.10.024  0.662
2012 McLaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck. Head & Neck. 34: 513-9. PMID 21584896 DOI: 10.1002/Hed.21759  0.461
2011 McLaughlin PJ, Pothering CA, Immonen JA, Zagon IS. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats. Experimental Biology and Medicine (Maywood, N.J.). 236: 1122-32. PMID 21917593 DOI: 10.1258/Ebm.2011.011163  0.46
2011 Zagon IS, McLaughlin PJ. Targeting opioid signaling in Crohn's disease: new therapeutic pathways. Expert Review of Gastroenterology & Hepatology. 5: 555-8. PMID 21910569 DOI: 10.1586/Egh.11.62  0.402
2011 Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Experimental Biology and Medicine (Maywood, N.J.). 236: 1036-50. PMID 21807817 DOI: 10.1258/Ebm.2011.011121  0.715
2011 Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Experimental Biology and Medicine (Maywood, N.J.). 236: 883-95. PMID 21685240 DOI: 10.1258/Ebm.2011.011096  0.707
2011 Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecologic Oncology. 122: 382-8. PMID 21531450 DOI: 10.1016/J.Ygyno.2011.04.009  0.715
2011 Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. Brain Research. 1381: 243-53. PMID 21256121 DOI: 10.1016/J.Brainres.2011.01.036  0.62
2011 Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology. 216: 579-90. PMID 20965606 DOI: 10.1016/J.Imbio.2010.09.014  0.681
2011 Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology. 216: 173-83. PMID 20598772 DOI: 10.1016/j.imbio.2010.06.001  0.682
2011 Donahue RN, Zagon IS, McLaughlin PJ. The Opioid Growth Factor Inhibits Established Ovarian Cancer in Nude Mice and Can Be Combined with Taxol or Cisplatin to Enhance Growth Inhibition Journal of Cancer Therapy. 2: 110-124. DOI: 10.4236/Jct.2011.22013  0.683
2010 McLaughlin PJ, Rogosnitzky M, Zagon IS. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors. Experimental Biology and Medicine (Maywood, N.J.). 235: 1292-9. PMID 20975079 DOI: 10.1258/Ebm.2010.010203  0.479
2010 Cheng F, McLaughlin PJ, Zagon IS. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking. Experimental Biology and Medicine (Maywood, N.J.). 235: 1093-101. PMID 20705629 DOI: 10.1258/Ebm.2010.010139  0.534
2010 Cheng F, McLaughlin PJ, Banks WA, Zagon IS. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 299: R774-85. PMID 20592180 DOI: 10.1152/Ajpregu.00318.2010  0.655
2010 Klocek MS, Sassani JW, Donahue RN, McLaughlin PJ, Zagon IS. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis. Investigative Ophthalmology & Visual Science. 51: 5054-61. PMID 20463323 DOI: 10.1167/Iovs.09-4949  0.803
2010 Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Research. 1310: 154-61. PMID 19931226 DOI: 10.1016/J.Brainres.2009.11.026  0.646
2010 Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 298: R459-66. PMID 19923357 DOI: 10.1152/Ajpregu.00646.2009  0.681
2010 Zagon IS, Sassani JW, Carroll MA, McLaughlin PJ. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Research Bulletin. 81: 248-55. PMID 19853024 DOI: 10.1016/J.Brainresbull.2009.10.009  0.416
2010 McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. Brain Research Bulletin. 81: 236-47. PMID 19683562 DOI: 10.1016/J.Brainresbull.2009.08.008  0.816
2010 McLaughlin PJ, Stucki J, Zagon IS. Abstract 697: Inhibition of Cancer Progression by Upregulation of the Opioid Growth Factor (OGF) - OGF Receptor (OGFr) Axis Using Imquimod or Low Dose Naltrexone Cancer Research. 70: 697-697. DOI: 10.1158/1538-7445.Am10-697  0.431
2010 Donahue RN, McLaughlin PJ, Zagon IS. Abstract 4153: Short term opioid receptor blockade inhibits cancer cell proliferation independent of immune function by upregulation of the OGF-OGFr axis: A tissue culture model of low dose naltrexone (LDN) Cancer Research. 70: 4153-4153. DOI: 10.1158/1538-7445.Am10-4153  0.702
2009 Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Archives of Ophthalmology (Chicago, Ill. : 1960). 127: 1468-73. PMID 19901212 DOI: 10.1001/Archophthalmol.2009.270  0.782
2009 Zagon IS, Rahn KA, Turel AP, McLaughlin PJ. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Experimental Biology and Medicine (Maywood, N.J.). 234: 1383-92. PMID 19855075 DOI: 10.3181/0906-Rm-189  0.625
2009 McLaughlin PJ, Zagon IS, Park SS, Conway A, Donahue RN, Goldenberg D. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis. Bmc Cancer. 9: 369. PMID 19835629 DOI: 10.1186/1471-2407-9-369  0.69
2009 Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 297: R1154-61. PMID 19675283 DOI: 10.1152/Ajpregu.00414.2009  0.693
2009 Cheng F, McLaughlin PJ, Banks WA, Zagon IS. Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 297: R844-52. PMID 19605761 DOI: 10.1152/Ajpregu.00311.2009  0.597
2009 Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Experimental Eye Research. 89: 686-92. PMID 19576213 DOI: 10.1016/J.Exer.2009.06.010  0.79
2009 Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 296: R1716-25. PMID 19297547 DOI: 10.1152/Ajpregu.00075.2009  0.698
2009 Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Experimental Biology and Medicine (Maywood, N.J.). 234: 532-41. PMID 19244545 DOI: 10.3181/0901-Rm-16  0.591
2009 Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Molecular Biology of the Cell. 20: 319-27. PMID 18923142 DOI: 10.1091/Mbc.E08-07-0681  0.578
2009 Avella Patino D, Tagaram H, Kimchi E, McLaughlin P, Zagon I, Staveley-O'Carroll K. QS297. Opioid Growth Factor Inhibits Cell Replication and DNA Synthesis of Hepatocellular Cancer In Vitro Through a Receptor Mediated Mechanism Journal of Surgical Research. 151: 296. DOI: 10.1016/J.Jss.2008.11.603  0.459
2008 Goldenberg D, Zagon IS, Fedok F, Crist HS, McLaughlin PJ. Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer. Thyroid : Official Journal of the American Thyroid Association. 18: 1165-70. PMID 19014324 DOI: 10.1089/Thy.2008.0112  0.38
2008 McLaughlin PJ, Kreiner S, Morgan CR, Zagon IS. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. International Journal of Oncology. 33: 751-7. PMID 18813788 DOI: 10.3892/Ijo_00000061  0.394
2008 Zagon IS, Kreiner S, Heslop JJ, Conway AB, Morgan CR, McLaughlin PJ. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. International Journal of Oncology. 33: 317-23. PMID 18636152 DOI: 10.3892/Ijo_00000011  0.394
2008 Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Experimental Biology and Medicine (Maywood, N.J.). 233: 968-79. PMID 18480416 DOI: 10.3181/0802-Rm-58  0.681
2008 Zagon IS, Klocek MS, Griffith JW, Sassani JW, Komáromy AM, McLaughlin PJ. Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone. Archives of Ophthalmology (Chicago, Ill. : 1960). 126: 501-6. PMID 18413519 DOI: 10.1001/Archopht.126.4.501  0.783
2008 Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Molecular Cancer. 7: 5. PMID 18190706 DOI: 10.1186/1476-4598-7-5  0.574
2008 Goldenberg D, Zagon I, McLaughlin PJ. QS106. The Opioid Growth Factor Axis in Human Thyroid Cancer Journal of Surgical Research. 144: 310. DOI: 10.1016/J.Jss.2007.12.346  0.41
2007 Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Research. 67: 10511-8. PMID 17974995 DOI: 10.1158/0008-5472.Can-07-1922  0.595
2007 Zagon IS, Rahn KA, McLaughlin PJ. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides. 41: 441-52. PMID 17910895 DOI: 10.1016/J.Npep.2007.08.002  0.663
2007 Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Archives of Ophthalmology (Chicago, Ill. : 1960). 125: 1082-8. PMID 17698755 DOI: 10.1001/Archopht.125.8.1082  0.776
2007 Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 23: 89-102. PMID 17444796 DOI: 10.1089/Jop.2006.0111  0.795
2007 Zagon IS, Verderame MF, Hankins J, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. International Journal of Oncology. 30: 775-83. PMID 17332915 DOI: 10.3892/Ijo.30.4.775  0.458
2007 Zagon IS, Sassani JW, Myers RL, McLaughlin PJ. Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium. Brain Research Bulletin. 72: 18-24. PMID 17303503 DOI: 10.1016/J.Brainresbull.2006.12.007  0.399
2007 McLaughlin PJ, Verderame MF, Hankins JL, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. International Journal of Molecular Medicine. 19: 421-8. PMID 17273790 DOI: 10.3892/Ijmm.19.3.421  0.447
2006 Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Archives of Ophthalmology (Chicago, Ill. : 1960). 124: 1620-4. PMID 17102011 DOI: 10.1001/Archopht.124.11.1620  0.45
2006 Zagon IS, Klocek MS, Sassani JW, Mauger DT, McLaughlin PJ. Corneal safety of topically applied naltrexone. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 22: 377-87. PMID 17076633 DOI: 10.1089/Jop.2006.22.377  0.795
2006 Zagon IS, Sassani JW, McLaughlin PJ. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea. 25: 821-9. PMID 17068460 DOI: 10.1097/01.Ico.0000224646.66472.Aa  0.429
2006 Zagon IS, McLaughlin PJ. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. International Journal of Oncology. 29: 489-94. PMID 16820893 DOI: 10.3892/Ijo.29.2.489  0.453
2006 McLaughlin PJ, Zagon IS. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. International Journal of Oncology. 28: 1577-83. PMID 16685459 DOI: 10.3892/Ijo.28.6.1577  0.426
2006 Zagon IS, Sassani JW, McLaughlin PJ. Insulin treatment ameliorates impaired corneal reepithelialization in diabetic rats. Diabetes. 55: 1141-7. PMID 16567540 DOI: 10.2337/Diabetes.55.04.06.Db05-1581  0.383
2006 Hurst WJ, McLaughlin PJ, Zagon IS, Rogosnitzky M. Stability of opioid growth factor ([Met5]-enkephalin) in solution using HPLC and photodiode array detection Journal of Liquid Chromatography and Related Technologies. 29: 151-157. DOI: 10.1080/10826070500416395  0.354
2006 McLaughlin PJ. Proenkephalin-Derived Opioid Peptides Handbook of Biologically Active Peptides. 1313-1318. DOI: 10.1016/B978-012369442-3/50185-9  0.344
2005 Zagon IS, McLaughlin PJ. Opioids and differentiation in human cancer cells. Neuropeptides. 39: 495-505. PMID 16169076 DOI: 10.1016/J.Npep.2005.07.001  0.479
2005 Zagon IS, Sassani JW, Verderame MF, McLaughlin PJ. Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea. 24: 614-9. PMID 15968171 DOI: 10.1097/01.Ico.0000153561.89902.57  0.455
2005 Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology. 56: 510-20. PMID 15947928 DOI: 10.1007/S00280-005-1028-X  0.449
2005 Jaglowski JR, Zagon IS, Stack BC, Verderame MF, Leure-duPree AE, Manning JD, McLaughlin PJ. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology. 56: 97-104. PMID 15791460 DOI: 10.1007/S00280-004-0929-4  0.415
2005 McLaughlin PJ, Jaglowski JR, Verderame MF, Stack BC, Leure-Dupree AE, Zagon IS. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. International Journal of Oncology. 26: 809-16. PMID 15703840 DOI: 10.3892/Ijo.26.3.809  0.441
2005 Zagon IS, Ruth TB, McLaughlin PJ. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium. The Anatomical Record. Part a, Discoveries in Molecular, Cellular, and Evolutionary Biology. 282: 24-37. PMID 15584033 DOI: 10.1002/Ar.A.20161  0.411
2004 Zagon IS, McLaughlin PJ. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. International Journal of Oncology. 24: 1443-8. PMID 15138586 DOI: 10.3892/Ijo.24.6.1443  0.49
2004 Zagon IS, McLaughlin PJ. Gene expression of OGFr in the developing and adult rat brain and cerebellum. Brain Research Bulletin. 63: 57-63. PMID 15121239 DOI: 10.1016/J.Brainresbull.2003.12.002  0.391
2004 Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anti-Cancer Drugs. 15: 203-9. PMID 15014352 DOI: 10.1097/00001813-200403000-00003  0.351
2004 McLaughlin PJ, Stack BC, Braine KM, Ruda JD, Zagon IS. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. International Journal of Oncology. 24: 227-32. PMID 14654962 DOI: 10.3892/Ijo.24.1.227  0.446
2003 Zagon IS, Verderame MF, McLaughlin PJ. The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides. 37: 290-7. PMID 14607106 DOI: 10.1016/J.Npep.2003.07.001  0.479
2003 McLaughlin PJ, Levin RJ, Zagon IS. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Letters. 199: 209-17. PMID 12969794 DOI: 10.1016/S0304-3835(03)00341-0  0.477
2003 Sassani JW, Zagon IS, McLaughlin PJ. Opioid growth factor modulation of corneal epithelium: uppers and downers. Current Eye Research. 26: 249-62. PMID 12854052 DOI: 10.1076/Ceyr.26.4.249.15427  0.499
2003 Zagon IS, McLaughlin PJ. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 37: 79-88. PMID 12747939 DOI: 10.1016/S0143-4179(03)00007-6  0.488
2003 McLaughlin PJ, Stack BC, Levin RJ, Fedok F, Zagon IS. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck. Cancer. 97: 1701-10. PMID 12655527 DOI: 10.1002/Cncr.11237  0.402
2003 Zagon IS, Ruth TB, Leure-duPree AE, Sassani JW, McLaughlin PJ. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Research. 967: 37-47. PMID 12650964 DOI: 10.1016/S0006-8993(02)04172-0  0.393
2003 Zagon IS, Essis FM, Verderame MF, Healy DA, Atnip RG, McLaughlin PJ. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery. Journal of Vascular Surgery. 37: 636-43. PMID 12618704 DOI: 10.1067/Mva.2003.165  0.479
2002 Smith JP, Verderame MF, McLaughlin P, Martenis M, Ballard E, Zagon IS. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. International Journal of Molecular Medicine. 10: 689-94. PMID 12429993 DOI: 10.3892/Ijmm.10.6.689  0.367
2002 McLaughlin PJ. Exposure to the opioid antagonist naltrexone throughout gestation alters postnatal heart development. Biology of the Neonate. 82: 207-16. PMID 12373072 DOI: 10.1159/000063611  0.403
2002 Zagon IS, Jenkins JB, Sassani JW, Wylie JD, Ruth TB, Fry JL, Lang CM, McLaughlin PJ. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes. 51: 3055-62. PMID 12351447 DOI: 10.2337/Diabetes.51.10.3055  0.452
2002 Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Research. Brain Research Reviews. 38: 351-76. PMID 11890982 DOI: 10.1016/S0165-0173(01)00160-6  0.463
2002 Blebea J, Vu JH, Assadnia S, McLaughlin PJ, Atnip RG, Zagon IS. Differential effects of vascular growth factors on arterial and venous angiogenesis. Journal of Vascular Surgery. 35: 532-8. PMID 11877704 DOI: 10.1067/Mva.2002.120042  0.306
2002 McLaughlin PJ, Wylie JD, Bloom G, Griffith JW, Zagon IS. Chronic exposure to the opioid growth factor, [Met5]-enkephalin, during pregnancy: maternal and preweaning effects. Pharmacology, Biochemistry, and Behavior. 71: 171-81. PMID 11812520 DOI: 10.1016/S0091-3057(01)00649-9  0.402
2001 Zagon IS, Wylie JD, Hurst WJ, McLaughlin PJ. Transplacental transfer of the opioid growth factor, [Met(5)]-enkephalin, in rats. Brain Research Bulletin. 55: 341-6. PMID 11489341 DOI: 10.1016/S0361-9230(01)00518-4  0.404
2000 Zagon IS, Verderame MF, Zimmer WE, McLaughlin PJ. Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse. Brain Research. Molecular Brain Research. 84: 106-14. PMID 11113537 DOI: 10.1016/S0169-328X(00)00232-1  0.423
2000 Zagon IS, Sassani JW, Ruth TB, McLaughlin PJ. Cellular dynamics of corneal wound re-epithelialization in the rat. III. Mitotic activity. Brain Research. 882: 169-79. PMID 11056196 DOI: 10.1016/S0006-8993(00)02864-X  0.334
2000 Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. International Journal of Oncology. 17: 1053-61. PMID 11029512 DOI: 10.3892/Ijo.17.5.1053  0.392
2000 Smith JP, Conter RL, Demers TM, McLaughlin PJ, Zagon IS. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer. Pancreas. 21: 158-64. PMID 10975710 DOI: 10.1097/00006676-200008000-00009  0.332
2000 Wilson RP, McLaughlin PJ, Lang CM, Zagon IS. The opioid growth factor, [Met5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin Cell Proliferation. 33: 63-73. PMID 10845251 DOI: 10.1046/J.1365-2184.2000.00161.X  0.489
2000 Zalys R, Zagon IS, Bonneau RH, Lang CM, McLaughlin PJ. In vivo effects of chronic treatment with [Met5]-enkephalin on hematological values and natural killer cell activity in athymic mice Life Sciences. 66: 829-834. PMID 10698357 DOI: 10.1016/S0024-3205(99)00655-4  0.466
2000 Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans Brain Research. 856: 75-83. PMID 10677613 DOI: 10.1016/S0006-8993(99)02330-6  0.434
2000 McLaughlin PJ, Levin RJ, Zagon IS. The opioid growth factor receptor in human head and neck squamous cell carcinoma International Journal of Molecular Medicine. 5: 191-196. PMID 10639600 DOI: 10.3892/Ijmm.5.2.191  0.423
2000 Zagon IS, Smith JP, Conter R, McLaughlin PJ. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma International Journal of Molecular Medicine. 5: 77-84. PMID 10601579 DOI: 10.1016/S0016-5085(00)80450-3  0.402
2000 Zagon IS, Smith JP, Roesener CD, Verderame MF, McLaughlin PJ. Cell cycle alterations and the inhibition of humanpancreatic cell replication by opioid growth factor Gastroenterology. 118: A563. DOI: 10.1016/S0016-5085(00)84386-3  0.454
2000 Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal wcation, and function of a cdna encoding the opioid growth factor receptor (OGFR) in humans and a modulator of ogf activity in the growth of pancreatic and colorectal cancer Gastroenterology. 118: A417. DOI: 10.1016/S0016-5085(00)83780-4  0.394
2000 Ahmad M, Smith JP, Conter R, Harvey H, McLaughlin P, Bingaman S, Mauger DT, Zagon IS. Treatment of advanced pancreatic cancer patients with opioid growth factor The American Journal of Gastroenterology. 95: 2471-2472. DOI: 10.1016/S0002-9270(00)01358-7  0.429
1999 Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met5]enkephalin Brain Research. 849: 147-154. PMID 10592296 DOI: 10.1016/S0006-8993(99)02046-6  0.446
1999 Bisignani GJ, McLaughlin PJ, Ordille SD, Beltz MS, Jarowenko MV, Zagon IS. Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor Journal of Urology. 162: 2186-2191. PMID 10569617 DOI: 10.1016/S0022-5347(05)68157-8  0.471
1999 Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor and organ development in rat and human embryos Brain Research. 839: 313-322. PMID 10519055 DOI: 10.1016/S0006-8993(99)01753-9  0.508
1999 Zagon IS, Sassani JW, McLaughlin PJ. Cellular dynamics of corneal wound re-epithelialization in the rat. II. DNA synthesis of the ocular surface epithelium following wounding Brain Research. 839: 243-252. PMID 10519047 DOI: 10.1016/S0006-8993(99)01722-9  0.343
1999 McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by Opioid Growth Factor International Journal of Oncology. 14: 991-998. PMID 10200353 DOI: 10.3892/Ijo.14.5.991  0.49
1999 Zagon IS, Sassani JW, McLaughlin PJ. Cellular dynamics of corneal wound re-epithelialization in the rat I. Fate of ocular surface epithelial cells synthesizing DNA prior to wounding Brain Research. 822: 149-163. PMID 10082893 DOI: 10.1016/S0006-8993(99)01106-3  0.35
1999 Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor International Journal of Oncology. 14: 577-584. PMID 10024694 DOI: 10.3892/Ijo.14.3.577  0.49
1999 Mclaughlin PJ. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor International Journal of Oncology. 14: 373-380. PMID 9917516 DOI: 10.3892/Ijo.14.2.373  0.501
1998 Wilson RP, McLaughlin PJ, Lang CM, Zagon IS. Temporal variation in cellular proliferation during recornification of mouse tail skin Cell Proliferation. 31: 191-201. PMID 9925987 DOI: 10.1111/J.1365-2184.1998.Tb01197.X  0.31
1998 McLaughlin PJ, Allar MA. Preproenkephalin gene expression and [Met5]-enkephalin levels in the developing rat heart. Brain Research. Molecular Brain Research. 60: 160-7. PMID 9757025 DOI: 10.1016/S0169-328X(98)00178-8  0.391
1998 Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor Brain Research. 803: 61-68. PMID 9729280 DOI: 10.1016/S0006-8993(98)00610-6  0.489
1998 Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors Brain Research. 798: 254-260. PMID 9666142 DOI: 10.1016/S0006-8993(98)00427-2  0.493
1998 Zagon IS, Sassani JW, Wu Y, McLaughlin PJ. The autocrine derivation of the opioid growth factor, [Met5]- enkephalin, in ocular surface epithelium Brain Research. 792: 72-78. PMID 9593829 DOI: 10.1016/S0006-8993(98)00123-1  0.468
1998 Wu Y, Mclaughlin PJ, Zagon IS. Ontogeny of the opioid growth factor, [Met5]-enkephalin, preproenkephalin gene expression, and the ζ opioid receptor in the developing and adult aorta of rat Developmental Dynamics. 211: 327-337. PMID 9566952 DOI: 10.1002/(Sici)1097-0177(199804)211:4<327::Aid-Aja4>3.0.Co;2-J  0.475
1998 Mclaughlin PJ, Wu Y. Opioid gene expression in the developing and adult rat heart Developmental Dynamics. 211: 153-163. PMID 9489769 DOI: 10.1002/(Sici)1097-0177(199802)211:2<153::Aid-Aja4>3.0.Co;2-G  0.391
1998 Zagon IS, Hurst WJ, McLaughlin PJ. Naltrexone is not detected in preweaning rats following transplacental exposure: implications for growth modulation. Life Sciences. 62: 221-8. PMID 9488100 DOI: 10.1016/S0024-3205(97)01090-4  0.42
1998 Smith JP, Shih AH, Wotring MG, McLaughlin PJ, Zagon IS. Characterization of CCK-B/gastrin-like receptors in human gastric carcinoma International Journal of Oncology. 12: 411-419. PMID 9458369 DOI: 10.3892/Ijo.12.2.411  0.343
1998 Zagon IS, Tobias SW, Hytrek SD, McLaughlin PJ. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters μ opioid receptors Pharmacology Biochemistry and Behavior. 59: 201-207. PMID 9443556 DOI: 10.1016/S0091-3057(97)00419-X  0.475
1998 Bartek JP, Healy DA, Smilanich RP, Essis FM, McLaughlin PJ, Zagon IS. Opioid Growth Factor Decreases Neointima Formation in the Rat Carotid Artery Journal of Vascular and Interventional Radiology. 9: 711. DOI: 10.1016/S1051-0443(98)70380-X  0.401
1997 Zagon IS, Tobias SW, McLaughlin PJ. Endogenous opioids and prenatal determinants of neuroplasticity Advances in Experimental Medicine and Biology. 429: 289-303. PMID 9413582 DOI: 10.1007/978-1-4757-9551-6_21  0.48
1997 McLaughlin PJ, Tobias SW, Lang CM, Zagon IS. Opioid receptor blockade during prenatal life modifies postnatal behavioral development Pharmacology Biochemistry and Behavior. 58: 1075-1082. PMID 9408216 DOI: 10.1016/S0091-3057(97)00307-9  0.432
1997 Zagon IS, Hurst WJ, McLaughlin PJ. Transplacental transfer of naltrexone in rats. Life Sciences. 61: 1261-7. PMID 9324068 DOI: 10.1016/S0024-3205(97)00671-1  0.387
1997 Zagon IS, Hurst WJ, McLaughlin PJ. Identification of [Met5]-enkephalin in developing, adult, and renewing tissues by reversed-phase high performance liquid chromatography and radioimmunoassay. Life Sciences. 61: 363-70. PMID 9244362 DOI: 10.1016/S0024-3205(97)00393-7  0.3
1997 McLaughlin PJ, Wu Y. Identification and characterization of the ζ-opioid receptor in developing rat heart American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 272. PMID 9227598 DOI: 10.1152/Ajpregu.1997.272.6.R1841  0.407
1997 Zagon IS, Sassani JW, Kane ER, McLaughlin PJ. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Research. 759: 92-102. PMID 9219867 DOI: 10.1016/S0006-8993(97)00238-2  0.483
1997 Levin RJ, Wu Y, McLaughlin PJ, Zagon IS. Expression of the opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma Laryngoscope. 107: 335-339. PMID 9121309 DOI: 10.1097/00005537-199703000-00011  0.462
1997 Zagon IS, Hytrek SD, Smith JP, McLaughlin PJ. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice Cancer Letters. 112: 167-175. PMID 9066724 DOI: 10.1016/S0304-3835(96)04566-1  0.444
1997 Zagon IS, McLaughlin PJ. Opioid growth factor is present in human and mouse gastrointestinal tract and inhibits DNA synthesis American Journal of Physiology. 272.  0.416
1997 Levin RJ, Wu Y, McLaughlin PJ, Zagon IS. Presence and distribution of opioid growth factor, [Met5]-enkephalin and ζ-opioid receptor in head and neck squamous cell carcinoma Faseb Journal. 11: A429.  0.339
1996 Isayama T, McLaughlin PJ, Zagon IS. Ontogeny of preproenkephalin mRNA expression in the rat retina. Visual Neuroscience. 13: 695-704. PMID 8870226 DOI: 10.1017/S0952523800008580  0.397
1996 Smith JP, Stock EA, Wotring MG, Mclaughlin PJ, Zagon IS. Characterization of the CCK-B/gastrin-like receptor in human colon cancer American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 271: R797-R805. PMID 8853405 DOI: 10.1152/Ajpregu.1996.271.3.R797  0.355
1996 Zagon IS, Hytrek SD, Lang CM, Smith JP, Mcgarrity TJ, Wu Y, Mclaughlin PJ. Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 271: R780-R786. PMID 8853403 DOI: 10.1152/Ajpregu.1996.271.3.R780  0.471
1996 Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 271: R511-R518. PMID 8853370 DOI: 10.1152/Ajpregu.1996.271.3.R511  0.501
1996 Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor-dependent DNA synthesis in the neonatal rat aorta American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 270: R22-R32. PMID 8769781 DOI: 10.1152/Ajpregu.1996.270.1.R22  0.501
1996 McLaughlin PJ. Regulation of DNA synthesis of myocardial and epicardial cells in developing rat heart by [Met5]enkephalin American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 271. PMID 8760212 DOI: 10.1152/Ajpregu.1996.271.1.R122  0.48
1996 Hytrek SD, Smith JP, McGarrity TJ, McLaughlin PJ, Lang CM, Zagon LS. Identification and characterization of ζ-opioid receptor in human colon cancer American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 271. PMID 8760211 DOI: 10.1152/Ajpregu.1996.271.1.R115  0.404
1996 Zagon IS, Wu Y, McLaughlin PJ. The opioid growth factor, [Met5]-enkephalin, and the ζ (zeta) opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis Journal of Investigative Dermatology. 106: 490-497. PMID 8648182 DOI: 10.1111/1523-1747.Ep12343712  0.494
1996 Hytrek SD, McLaughlin PJ, Lang CM, Zagon IS. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone Cancer Letters. 101: 159-164. PMID 8620464 DOI: 10.1016/0304-3835(96)04119-5  0.46
1996 McLaughlin PJ, Zagon IS. Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion American Journal of Physiology. 270: R1078-R1084. DOI: 10.1152/Ajpregu.1996.270.5.R1078  0.34
1996 Wu Y, McLaughlin PJ, Zagon IS. Opioid growth factor and the zeta (f) opioid receptor are present and function in mammalian esophagus Faseb Journal. 10: A771.  0.326
1996 McLaughlin PJ, Wu Y, Zaeon IS. An endogenous opioid system is present and modulates dna synthesis during fetal rat development Faseb Journal. 10.  0.38
1995 Isayama T, Hurst WJ, McLaughlin PJ, Zagon IS. Ontogeny of the opioid growth factor, [Met5]-enkephalin, and its binding activity in the rat retina. Visual Neuroscience. 12: 939-50. PMID 8924417 DOI: 10.1017/S0952523800009494  0.305
1995 Zagon IS, McLaughlin PJ. Gene-peptide relationships in the developing rat brain: the response of preproenkephalin rnRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure Molecular Brain Research. 33: 111-120. PMID 8774952 DOI: 10.1016/0169-328X(95)00119-D  0.46
1995 Zagon IS, Sassani JW, McLaughlin PJ. Opioid growth factor modulates corneal epithelial outgrowth in tissue culture American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 268: R942-R950. PMID 7733405 DOI: 10.1152/Ajpregu.1995.268.4.R942  0.512
1995 Zagon IS, Sassani JW, Allison G, McLaughlin PJ. Conserved expression of the opioid growth factor, [Met5]enkephalin, and the zeta (ζ) opioid receptor in vertebrate cornea Brain Research. 671: 105-111. PMID 7728521 DOI: 10.1016/0006-8993(94)01314-8  0.499
1994 Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. The American Journal of Physiology. 266: R277-83. PMID 8304551 DOI: 10.1152/Ajpregu.1994.266.1.R277  0.349
1994 McLaughlin PJ. Opioid antagonist modulation of rat heart development Life Sciences. 54: 1423-1431. PMID 8190015 DOI: 10.1016/0024-3205(94)00597-4  0.463
1994 Zagon IS, Isayama T, McLaughlin PJ. Preproenkephalin mRNA expression in the developing and adult rat brain. Brain Research. Molecular Brain Research. 21: 85-98. PMID 8164525 DOI: 10.1016/0169-328X(94)90381-6  0.4
1994 Zagon IS, Yan W, McLaughlin PJ. Opioid antagonist modulation of DNA synthesis in mouse tongue epithelium is circadian dependent Pharmacology, Biochemistry and Behavior. 48: 709-714. PMID 7938126 DOI: 10.1016/0091-3057(94)90337-9  0.475
1994 Zagon IS, Wu Yan, McLaughlin PJ. Opioid growth factor inhibits DNA synthesis in mouse tongue epithelium in a circadian rhythm-dependent manner Am.J.Physiol.. 267: R645-R652. DOI: 10.1152/Ajpregu.1994.267.3.R645  0.459
1994 Zagon IS, Wu Yan, McLaughlin PJ. Opioid growth factor inhibits DNA synthesis in mouse tongue epithelium in a circadian rhythm-dependent manner Am.J.Physiol.. 267.  0.302
1993 Zagon IS, Goodman SR, McLaughlin PJ. Zeta (ζ), the opioid growth factor receptor: identification and characterization of binding subunits Brain Research. 605: 50-56. PMID 8385541 DOI: 10.1016/0006-8993(93)91355-V  0.425
1993 Smith JP, Rickabaugh CA, McLaughlin PJ, Zagon IS. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells American Journal of Physiology - Gastrointestinal and Liver Physiology. 265: G149-G155. PMID 8338163 DOI: 10.1152/Ajpgi.1993.265.1.G149  0.373
1993 Zagon IS, McLaughlin PJ. Production and characterization of polyclonal and monoclonal antibodies to the zeta (ξ) opioid receptor Brain Research. 630: 295-302. PMID 8118696 DOI: 10.1016/0006-8993(93)90669-E  0.364
1992 Zagon IS, Gibo DM, McLaughlin PJ. Ontogeny of zeta (ζ), the opioid growth factor receptor, in the rat brain Brain Research. 596: 149-156. PMID 1334774 DOI: 10.1016/0006-8993(92)91542-M  0.419
1992 Zagon IS, McLaughlin PJ. An opioid growth factor regulates the replication of microorganisms Life Sciences. 50: 1179-1187. PMID 1313136 DOI: 10.1016/0024-3205(92)90461-W  0.486
1991 Zagon IS, McLaughlin PJ. Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system Brain Research. 542: 318-323. PMID 2029640 DOI: 10.1016/0006-8993(91)91585-O  0.454
1991 Zagon IS, Gibo DM, McLaughlin PJ. Zeta (ξ), a growth-related opioid receptor in developing rat cerebellum: identification and characterization Brain Research. 551: 28-35. PMID 1655161 DOI: 10.1016/0006-8993(91)90909-F  0.426
1991 Isayama T, McLaughlin PJ, Zagon IS. Endogenous opioids regulate cell proliferation in the retina of developing rat. Brain Research. 544: 79-85. PMID 1649664 DOI: 10.1016/0006-8993(91)90887-2  0.504
1990 Zagon IS, McLaughlin PJ. Ultrastructural localization of enkephalin-like immunoreactivity in developing rat cerebellum Neuroscience. 34: 479-489. PMID 2333154 DOI: 10.1016/0306-4522(90)90156-X  0.351
1990 Zagon IS, McLaughlin PJ. Opioid antagonist (naltrexone) stimulation of cell proliferation in human and animal neuroblastoma and human fibrosarcoma cells in culture Neuroscience. 37: 223-226. PMID 2243594 DOI: 10.1016/0306-4522(90)90207-K  0.501
1990 Zagon IS, Gibo DM, McLaughlin PJ. Adult and developing human cerebella exhibit different profiles of opioid binding sites Brain Research. 523: 62-68. PMID 2169964 DOI: 10.1016/0006-8993(90)91635-T  0.395
1990 Zagon IS, Goodman SR, McLaughlin PJ. Demonstration and characterization of zeta (ζ), a growth-related opioid receptor, in a neuroblastoma cell line Brain Research. 511: 181-186. PMID 2159355 DOI: 10.1016/0006-8993(90)90159-9  0.448
1990 Zagon IS, Gibo D, McLaughlin PJ. Expression of zeta (ζ), a growth-related opioid receptor, in metastatic adenocarcinoma of the human cerebellum Journal of the National Cancer Institute. 82: 325-327. PMID 2153842 DOI: 10.1093/Jnci/82.4.325  0.432
1990 Zagon IS, McLaughlin PJ. Endogenous opioids, opioids receptors, and cancer Cancer Journal. 3: 101-103.  0.334
1989 Hauser KF, McLaughlin PJ, Zagon IS. Endogenous opioid systems and the regulation of dendritic growth and spine formation. The Journal of Comparative Neurology. 281: 13-22. PMID 2925898 DOI: 10.1002/Cne.902810103  0.48
1989 Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate growth of neural tumor cells in culture Brain Research. 490: 14-25. PMID 2758319 DOI: 10.1016/0006-8993(89)90425-3  0.495
1989 Zagon IS, Zagon E, McLaughlin PJ. Opioids and the developing organism: A comprehensive bibliography, 1984-1988 Neuroscience and Biobehavioral Reviews. 13: 207-235. PMID 2691928 DOI: 10.1016/S0149-7634(89)80055-7  0.37
1989 Zagon IS, McLaughlin PJ. Naloxone modulates body and organ growth of rats: Dependency on the duration of opioid receptor blockade and stereospecificity Pharmacology, Biochemistry and Behavior. 33: 325-328. PMID 2554339 DOI: 10.1016/0091-3057(89)90508-X  0.481
1989 Zagon IS, McLaughlin PJ. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors Brain Research. 480: 16-28. PMID 2540873 DOI: 10.1016/0006-8993(89)91562-X  0.502
1989 Zagon IS, Goodman SR, McLaughlin PJ. Characterization of zeta (zeta): a new opioid receptor involved in growth. Brain Research. 482: 297-305. PMID 2539884 DOI: 10.1016/0006-8993(89)91192-X  0.445
1988 Zagon IS, Goodman SR, McLaughlin PJ. Characterization of opioid binding sites in murine neuroblastoma Brain Research. 449: 80-88. PMID 2899449 DOI: 10.1016/0006-8993(88)91026-8  0.323
1988 Zagon IS, McLaughlin P. Endogenous opioids and the growth regulation of a neural tumor. Life Sciences. 43: 1313-8. PMID 2845218 DOI: 10.1016/0024-3205(88)90586-3  0.485
1987 McLaughlin PJ, Zagon IS. Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems Life Sciences. 41: 1465-1472. PMID 3041143 DOI: 10.1016/0024-3205(87)90711-9  0.487
1987 Hauser KF, McLaughlin PJ, Zagon IS. Endogenous opioids regulate dendritic growth and spine formation in developing rat brain. Brain Research. 416: 157-61. PMID 3040177 DOI: 10.1016/0006-8993(87)91509-5  0.448
1987 Zagon IS, McLaughlin PJ. Modulation of murine neuroblastoma in nude mice by opioid antagonists Journal of the National Cancer Institute. 78: 141-147. PMID 3025501 DOI: 10.1093/Jnci/78.1.141  0.457
1987 Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE. Opioid receptors and endogenous opioids in diverse human and animal cancers. Journal of the National Cancer Institute. 79: 1059-1065. DOI: 10.1093/Jnci/79.5.1059  0.452
1986 Zagon IS, Rhodes RE, McLaughlin PJ. Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat Cell and Tissue Research. 246: 561-565. PMID 3539353 DOI: 10.1007/Bf00215197  0.423
1986 Zagon IS, McLaughlin PJ. β-Funaltrexamine (β-FNA) and the regulation of body and brain development in rats Brain Research Bulletin. 17: 5-9. PMID 3019487 DOI: 10.1016/0361-9230(86)90155-3  0.381
1986 Zagon IS, McLaughlin PJ. Opioid antagonist-induced modulation of cerebral and hippocampal development: histological and morphometric studies Brain Research. 393: 233-246. PMID 3017514 DOI: 10.1016/0165-3806(86)90025-8  0.486
1986 Zagon I, McLaughlin P. Opioid antagonist (naltrexone) modulation of cerebellar development: histological and morphometric studies The Journal of Neuroscience. 6: 1424-1432. DOI: 10.1523/Jneurosci.06-05-01424.1986  0.492
1985 Zagon IS, Vaughn BV, McLaughlin PJ, Balaban CD. Localization of methadone in the brain of young rats by computer-assisted autoradiography. Neuroscience Research. 3: 1-19. PMID 4088543 DOI: 10.1016/0168-0102(85)90035-5  0.337
1985 Zagon IS, McLaughlin PJ. Opiate antagonist-induced regulation of organ development Physiology and Behavior. 34: 507-511. PMID 4011730 DOI: 10.1016/0031-9384(85)90041-1  0.405
1985 Zagon IS, McLaughlin PJ. Naltrexone's influence on neurobehavioral development Pharmacology, Biochemistry and Behavior. 22: 441-448. PMID 3991759 DOI: 10.1016/0091-3057(85)90046-2  0.389
1985 Zagon IS, Rhodes RE, McLaughlin PJ. Distribution of enkephalin immunoreactivity in germinative cells of developing rat cerebellum Science. 227: 1049-1051. PMID 3883485 DOI: 10.1126/Science.3883485  0.428
1985 Zagon IS, McLaughlin PJ. Stereospecific modulation of tumorigenicity by opioid antagonists European Journal of Pharmacology. 113: 115-120. PMID 2995053 DOI: 10.1016/0014-2999(85)90350-4  0.432
1985 Zagon IS, McLaughlin PJ. Endogenous opioids and brain development International Journal of Developmental Neuroscience. 3: 425-425. DOI: 10.1016/0736-5748(85)90103-0  0.372
1984 Zagon IS, McLaughlin PJ. Opioids alter tumor cell growth and differentiation in vitro Nida Research Monograph Series. 344-350. PMID 6434984  0.32
1984 Zagon IS, McLaughlin PJ. Naltrexone modulates body and brain development in rats: A role for endogenous opioid systems in growth Life Sciences. 35: 2057-2064. PMID 6092812 DOI: 10.1016/0024-3205(84)90563-0  0.456
1984 Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: A role for endogenous opioid systems in cancer Life Sciences. 35: 409-416. PMID 6087062 DOI: 10.1016/0024-3205(84)90651-9  0.418
1983 Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma Science. 221: 671-673. PMID 6867737 DOI: 10.1126/Science.6867737  0.377
1983 Zagon IS, McLaughlin PJ. Opioid antagonists inhibit the growth of metastatic murine neuroblastoma Cancer Letters. 21: 89-94. PMID 6640516 DOI: 10.1016/0304-3835(83)90087-3  0.413
1983 Zagon IS, Mclaughlin PJ. Increased brain size and cellular content in infant rats treated with an opiate antagonist Science. 221: 1179-1180. PMID 6612331 DOI: 10.1126/Science.6612331  0.402
1983 Zagon IS, McLaughlin PJ. Naltrexone modulates growth in infant rats Life Sciences. 33: 2449-2454. PMID 6316064 DOI: 10.1016/0024-3205(83)90639-2  0.451
1982 Zagon IS, McLaughlin PJ. Neuronal cell deficits following maternal exposure to methadone in rats Experientia. 38: 1214-1216. PMID 7140924 DOI: 10.1007/Bf01959747  0.301
1982 Zagon lS, McLaughlin PJ. Comparative Effects of postnatal undernutrition and methadone exposure on protein and nucleic acid contents of the brain and cerebellum in rats Developmental Neuroscience. 5: 385-393. PMID 6186450 DOI: 10.1159/000112698  0.306
1981 Zagon IS, McLaughlin PJ. Enhanced sensitivity to methadone in adult rats perinatally exposed to methadone Life Sciences. 29: 1137-1142. PMID 7289777 DOI: 10.1016/0024-3205(81)90202-2  0.332
1981 Zagon IS, McLaughlin PJ. Heroin prolongs survival time and retards tumor growth in mice with neuroblastoma Brain Research Bulletin. 7: 25-32. PMID 7272785 DOI: 10.1016/0361-9230(81)90094-0  0.336
1981 Zagon IS, McLaughlin PJ. Naloxone prolongs the survival time of mice treated with neuroblastoma Life Sciences. 28: 1095-1102. PMID 7231040 DOI: 10.1016/0024-3205(81)90686-X  0.344
1981 Zagon IS, McLaughlin PJ. Withdrawal-like symptoms in young and adult rats maternally exposed to methadone Pharmacology, Biochemistry and Behavior. 15: 887-894. PMID 7198796 DOI: 10.1016/0091-3057(81)90049-6  0.353
1981 Zagon IS, McLaughlin PJ. Nucleic acids and protein in brains and cerebella of rats transplacentally exposed to ethylnitrosourea Brain Research Bulletin. 6: 355-360. PMID 6166356 DOI: 10.1016/S0361-9230(81)80003-2  0.304
1980 McLaughlin PJ, Zagon IS. Body and organ development of young rats maternally exposed to methadone. Biology of the Neonate. 38: 185-96. PMID 7407276 DOI: 10.1159/000241363  0.321
1980 Zagon IS, McLaughlin PJ. Protracted analgesia in young and adult rats maternally exposed to methadone Experientia. 36: 329-330. PMID 7371790 DOI: 10.1007/Bf01952306  0.327
1979 Zagon IS, Mclaughlin PJ, Thompson CI. Development of motor activity in young rats following perinatal methadone exposure Pharmacology, Biochemistry and Behavior. 10: 743-749. PMID 493289 DOI: 10.1016/0091-3057(79)90327-7  0.358
1978 Zagon IS, McLaughlin PJ. Perinatal methadone exposure and its influence on the behavioral ontogeny of rats Pharmacology, Biochemistry and Behavior. 9: 665-672. PMID 733856 DOI: 10.1016/0091-3057(78)90219-8  0.347
1978 Zagon IS, McLaughlin PJ. Perinatal methadone exposure and brain development: A biochemical study Journal of Neurochemistry. 31: 49-54. PMID 671039 DOI: 10.1111/J.1471-4159.1978.Tb12431.X  0.324
1977 Zagon IS, McLaughlin PJ. Methadone and brain development Experientia. 33: 1486-1487. PMID 923719 DOI: 10.1007/Bf01918824  0.302
1977 Zagon IS, McLaughlin PJ. Effect of chronic maternal methadone exposure on perinatal development Neonatology. 31: 271-282. PMID 911959 DOI: 10.1159/000240975  0.315
1977 Zagon IS, McLaughlin PJ. Effects of chronic morphine administration on pregnant rats and their offspring Pharmacology. 15: 302-310. PMID 896945 DOI: 10.1159/000136703  0.366
1977 Zagon IS, McLaughlin PJ. The effects of different schedules of methadone treatment on rat brain development Experimental Neurology. 56: 538-552. PMID 885202 DOI: 10.1016/0014-4886(77)90320-X  0.351
1977 Zagon IS, McLaughlin PJ. Morphine and brain growth retardation in the rat Pharmacology. 15: 276-282. PMID 866403 DOI: 10.1159/000136699  0.365
Show low-probability matches.